SHARP Launches New A3 Colour Multifunction Printers in India, Makes Everyday Office Tasks Simpler and Smarter
New Delhi [India], June 20: SHARP Business Systems (India) Pvt. Ltd., a wholly owned Indian subsidiary of SHARP Corporation, Japan, has launched its latest A3 colour multifunction printer (MFP) series in India during the SHARP National Dealer Meet 2025 and Silver Jubilee Celebrations. Designed to redefine office efficiency and meet the evolving demands of Indian businesses, the newly introduced models -- BP-22C20/BP-22C20T and BP-22C25/BP-22C25T -- are built to enhance productivity with copy and print speeds of 20 PPM and 25 PPM respectively. These models combine performance, compactness, and cost-effective colour output in a single robust device.
The BP-22C series MFPs bring an optimal mix of functionality and design, offering one of the most compact footprints in their class. These models are designed to seamlessly integrate into dynamic work environments including SMEs, corporate offices, co-working spaces, healthcare, and educational institutions. With a 7-inch intuitive touch panel, users can easily access key functions and simplify document handling through smart features such as Rotated Output for Copy and duplex printing - streamlining tasks across both portrait and landscape formats with ease.
"Indian offices today are looking for smart, reliable machines that don't take up too much space but still get the job done well. That's exactly what the BP-22C series is about. It's practical, easy to use, and brings colour printing within reach--without making it complicated or expensive, "said Mr. Osamu Narita, Managing Director - SHARP Business Systems, India.
"We designed this series with real work situations in mind--busy teams, limited space, and the need for quick results. Whether it's scanning, printing or sharing documents on the go, the BP-22C20 and BP-22C25 offer the flexibility and performance that fit right into Indian workplaces, "said Mr. Sukhdev Singh, President - Smart Business Solutions, SHARP Business Systems, India.
Innovative Design and Exceptional Connectivity
Engineered to support diverse office workflows, the BP-22C series offers consistent print speeds of up to 20/25 pages per minute in both colour and monochrome. With 2 GB RAM and 16 GB eMMC storage, the devices support high-efficiency operations, including PCL printing, quick warm-up, and an expanded paper capacity of up to 1,850 sheets for uninterrupted tasks.
The series also stands out for its enhanced mobile connectivity--users can print and scan directly from smartphones via the Sharpdesk Mobile app. Compatibility with AirPrint allows seamless integration with iOS devices, while USB Direct Print functionality further adds convenience for users needing quick access. Optional wireless connectivity ensures flexibility, especially in office environments lacking LAN infrastructure.
Additionally, advanced features like the 100-sheet Reversing Single Pass Feeder with 31 OPM scan speed and multiple destination options (email, FTP, USB) make the BP-22C series a practical choice for busy offices managing high-volume document workflows.
"Businesses today are looking for solutions that balance versatility and efficiency," said Jun Kasawaki, Head of Asia Business Solutions Centre, Thailand, SHARP. "The BP-22C series is designed to cater to the evolving needs of the modern workplace, where space is limited but performance expectations are high. With its combination of vibrant colour printing, exceptional monochrome functionality, and energy-efficient operation, the BP-22C series enables businesses to stay ahead of the curve, delivering high-quality colour documents on demand while minimizing operational costs."
Security and Sustainability at the Forefront
SHARP has prioritized security in the BP-22C series, offering password-based user authentication and secure job retention. IT administrators can also benefit from secure data erasure protocols when decommissioning the device--ensuring complete data privacy and regulatory compliance.
On the sustainability front, these ENERGY STAR® certified MFPs consume as little as 0.5W in network standby mode, reducing power usage and supporting environmentally responsible operations--a key consideration for Indian enterprises looking to align with green practices.
A Powerful Solution for India's Diverse Business Ecosystem
Whether in small businesses, educational institutions, hospitals, or government offices, the SHARP BP-22C series provides a cost-efficient solution with high-quality colour printing, fast performance, and robust mobile support. These MFPs offer Indian enterprises the opportunity to enhance office productivity while maintaining low operational costs.
The BP-22C20/BP-22C20T and BP-22C25/BP-22C25T will be available across India through SHARP's network of offices and authorized channel partners, with pricing starting from INR 2,97,500.
About SHARP Business Systems (India)
SHARP Business Systems (India) Pvt Ltd is an ISO 900l: 2015 Certified and wholly owned Indian subsidiary of SHARP Corporation, Japan which is a 112-year-old company with many technological innovations. Supported by a well-trained sales and service force, our business provides a host of market leading B2B and B2C products that includes a comprehensive range of the latest office Solutions, Visual Solutions and Home Solutions across India for over 25 years.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
6 minutes ago
- Time of India
Trump calls India's economy 'dead' – but that makes no sense
Recently, Donald Trump, the former U.S. President, made fun of India's economy by calling it 'dead.' But that's a strange and silly thing to say. Think about it: An economy is alive as long as people are buying, selling, and trading things — even if it's just one person giving a teabag to a friend in exchange for some biscuits. That's still trade! India has over 1.4 billion people, which means there are tons of trades and businesses happening every second. So how can it be 'dead'? Also, if India's economy was really dead, why is Trump so eager to sell things like soybeans, corn, and butter to India? You don't trade with something that isn't working. He even spent four months trying to make a trade deal — and only gave up when he got frustrated and added extra taxes (called tariffs) on Indian goods. India's economy is actually growing faster than any other big country's right now. That's not what a dead economy looks like. Even countries that aren't growing fast — like Japan — are still very much alive and running. Trump has said strange things before. Once, he told a man his father would be proud 'looking down on him,' thinking the father had passed away. But the man said his dad was still alive. Trump just replied, 'Then he's even more proud!' So when Trump says 'dead,' it might not mean what you think — or it might not mean anything at all. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
Mint
6 minutes ago
- Mint
India unveils first formal rules for drug approval panels in regulatory overhaul
New Delhi: India has issued its first formal playbook for how expert panels should vet new drugs, biologics and medical devices—a move aimed at fixing long-standing concerns about inconsistent and opaque approvals that have delayed critical drug launches and eroded industry trust in the regulatory system. The guidelines, issued by the Central Drugs Standard Control Organization (CDSCO), represent a major overhaul of India's drug approval process and aim to make regulatory decisions faster, more predictable and transparent, according to two government officials and documents reviewed by Mint. The guidelines standardize how Subject Expert Committees (SECs) are formed, how members are selected, and how they must evaluate applications, including the scientific benchmarks and disclosure norms they must follow. The SECs advise the Drugs Controller General of India (DCGI) on whether to clear new drugs, and their decisions have long shaped the trajectory of India's pharmaceutical industry. The CDSCO finalized the guidelines about two weeks ago and circulated them to SEC members for immediate implementation, the officials said. The overhaul follows recommendations from the World Health Organization (WHO), which last year conducted a regulatory review of CDSCO and the office of the DCGI, who heads the organization. The WHO called for stronger transparency and data integrity to align India's system with global standards. India's pharmaceutical industry ranks third globally by volume and 14th by value. It accounts for roughly 20% of the world's generic drug supply and manufactures more than 60,000 products across 60 therapeutic areas. The sector also includes over-the-counter drugs, vaccines, contract manufacturing, biologics and biosimilars. As part of its findings, the WHO urged Indian authorities to implement stronger controls to prevent, detect, and respond to substandard and falsified medical products; to launch a market surveillance program for drug quality monitoring; and to ensure that promotional and advertising claims for medicines are not misleading. These steps are now being implemented by the DCGI and other stakeholders involved in the SEC meetings, according to the officials cited earlier. The SECs play a central role in India's drug approval process, advising the DCGI on whether to approve new drugs, biologics, and medical devices. Each committee includes eight experts—one pharmacologist and seven specialists from research, medical, or regulatory institutions—and requires a four-member quorum to issue recommendations. In the absence of formal guidelines, though, these decisions were often viewed as inconsistent or opaque, delaying product approvals. 'SECs are subject expert committees involved in evaluating approvals of new drugs. Simplification and streamlining the process will help industry in getting drugs approved with predictable speed and more transparency. We appreciate the step taken by DCGI," said Dr. Viranchi Shah, national spokesperson of the Indian Drugs Manufacturers Association (IDMA). Emailed queries to the spokesperson for the health ministry went unanswered at the time of publishing. Clearer mandate, tougher benchmarks According to the guidance document, SEC members must meet strict selection criteria, including a publication record of at least 10 peer-reviewed papers and a citation ratio of 2:1. Experts are appointed for a three-year term and are expected to maintain confidentiality, impartiality, and active participation. Those who fail to attend meetings regularly may be removed. The document specifies that SECs must offer rigorous, science-based evaluations on safety, efficacy, and risk-benefit balance. It outlines the dos and don'ts of deliberations: clinical trial waiver decisions must include clear yes/no recommendations with detailed justifications, and all discussions must remain focused on scientific and regulatory issues, excluding matters such as pricing. 'For new drug and clinical trial applications, the DCGI refers them to the SEC, an expert body that discusses proposals and offers recommendations for approval or rejection. These experts, being external to CDSCO, are not always fully aware of regulatory requirements. This often led to differing, sometimes subjective opinions, a lack of uniformity in decisions, and delays on straightforward matters. Therefore, it's important for the committee to provide uniform decisions, maintain transparency, and offer proper reasoning for approvals and rejections," said one of the two government officials cited earlier, who asked not to be named. The second official added, 'There were persistent discussions during SEC meetings about the absence of a guiding document to regulate or suggest proper functioning. This new guidance note outlines the 'do's and don'ts' for experts. Previously, some companies had even alleged that SEC meetings were not being conducted properly." While officials declined to cite specific past incidents, people familiar with the matter said the lack of consistency and alignment among SEC experts, who advise on key regulatory decisions, had severely affected the functioning of the DCGI in recent years. Industry seeks consistency For years, pharmaceutical companies have raised concerns over the unpredictability of SEC verdicts, especially around clinical trial waivers, which are critical for expediting the launch of generics and biosimilars. The new rules aim to reduce such uncertainty by standardizing decision-making across similar products, unless clear scientific reasons justify a deviation. The document states: 'The SECs are indispensable in the CDSCO's evaluation process due to their specialized expertise, independent perspective and commitment to quality assurance. These committees address complex scientific and regulatory challenges, fostering informed decision-making. By operating transparently and consistently across applications, SECs bolster public trust while safeguarding public health and promoting innovation in the healthcare sector." Public health experts have welcomed the reform. 'Any committee should operate under certain guidance, and it is always beneficial for all members of such a committee to have clarity and a common vision. It's akin to laying down the rules of the game," said Dr. Chandrakant Lahariya, a physician and public health expert. He added: 'The Subject Expert Committee (SEC) is an essential requirement for guiding the drug approvals and other processes in all regulatory bodies. When a new drug is needed, the SEC provides its recommendations to the apex drug regulator. CDSCO is a regulatory organization, and they need guidance from a technical expert committee to make decisions. A regulatory body needs guidance from those who deeply understand the subject."
The Hindu
36 minutes ago
- The Hindu
Trump welcomes reports India may halt Russian oil imports, calls it a 'good step'
U.S. President Donald Trump on Friday (August 1, 2025) expressed cautious optimism over reports that India may be ending its purchases of Russian oil, calling it a 'good step' while addressing reporters before departing the White House. 'I understand India no longer is going to be buying oil from Russia. That's what I heard. I don't know if that's right or not, but that's a good step,' Mr. Trump said during an impromptu press gaggle on the South Lawn. His remarks come amid growing American scrutiny of India's continued energy and defence ties with Russia, especially in the context of the ongoing war in Ukraine and broader U.S. efforts to isolate the Kremlin economically. While there has been no official confirmation from New Delhi regarding such a move, Mr. Trump's comments mark the first public acknowledgement from the U.S. administration of a potential policy shift by India. Mr. Trump has maintained a firm stance against countries maintaining close commercial ties with Moscow. His administration has already imposed a 25% tariff on Indian imports, citing both trade imbalances and India's longstanding energy relationship with Russia. In his remarks, Mr. Trump did not elaborate on whether the reported change in India's oil policy would impact those tariffs or future negotiations. 'We'll see what happens,' he said. The issue of India's energy imports from Russia has been a point of contention between Washington and New Delhi, with previous administrations urging India to reduce its reliance on Russian crude in the wake of the Ukraine conflict. India has so far defended its purchases as essential for energy security and economic stability. Mr. Trump's tone on Friday, however, suggested an openness to engage with India if the reported shift holds. 'That's a good step,' he repeated, signalling potential diplomatic movement should the reports prove accurate. Officials in New Delhi have historically avoided commenting on energy policy decisions until after implementation. Mr. Trump's brief but pointed remarks come as part of a broader foreign policy strategy to pressure both adversaries and allies into realigning their global partnerships in accordance with US strategic interests. Russia remains under sweeping U.S. sanctions, and energy exports have been a critical lifeline for the Kremlin amid ongoing war-related expenditures. (This article is published in an arrangement with 5WH.)
